Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality parameters

Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality parameters

  1. Merial EMEA
    Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality parameters
    Transcript Header:
    Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality parameters
    Transcript Body:
    • 1. Abstract accepted for 6th Asian Pig Veterinary Society congress, Ho Chi Minh City, Vietnam, September 23-25, 2013 PCV2 VACCINATION IN PIGLETS: A REVIEW OF COMPARATIVE TRIALS WITH CIRCOVAC® Olivier Merdy, Thaïs Vila, François Joisel MERIAL SAS, Lyon, France francois.joisel@merial.com Introduction PCV2 vaccination in piglets is now a routine practice worldwide to reduce the negative impact of infection on pig productivity from weaning onward. Among the commercial PCV2 vaccines available in the marketplace, CIRCOVAC is an inactivated adjuvanted vaccine registered for piglet and sow vaccination which has extensively proved its efficacy in particular on mortality and growth parameters. The aim of this paper is to review the literature comparing CIRCOVAC to other competitor PCV2 piglet vaccines in the field. Material and methods The review was performed in the proceedings of international and regional meetings focusing on porcine veterinary science. Field comparative trials and historical data records for which the experimental conditions could be verified and considered irreproachable were selected. Average daily weight gain (ADWG) and mortality rate were collected in the original paper. Parameters which were only reported in terms of difference between vaccinated groups without mention of average level were excluded. Results Among the 9 publications reviewed, there were 8 randomized trial and one historical data collection. The studies involved CIRCOVAC vaccination and 3 different competitor vaccines (A, B and C). All these studies were performed in farms with subclinical to endemic PCVD forms. Values are summarized in Tables 1 and 2. Table 1. Comparison of mortality rates following piglet vaccination with CIRCOVAC or competitor vaccines. Parameter Vaccine Parameter mean (%) Reference (year of publication) Mortality rate (W-S) CIRCOVAC 3.16nk Pinheiro et al. (2010) Vaccine A 2.5nk Vaccine B 3.3nk Mortality rate (D+R) CIRCOVAC 5.73nk Bardini et al. (2011) Vaccine A 6.26nk Mortality rate (W-S) CIRCOVAC 5.1a Tomás et al. (2011) Vaccine C 7.3b Mortality rate (W-S) CIRCOVAC 3.5a Waddilove AEJ. (2011) Vaccine A 4.5a Mortality rate (W-S) CIRCOVAC 8.5a Lopez et al. (2012) Vaccine A 8.1a Mortality rate (W-S) CIRCOVAC 2.18a Meyns et al. (2013) Vaccine A 3.17a Mortality rate (W-S) CIRCOVAC 4.4a Mortensen et al. (2013) - 3 farms Vaccine A 3.6a a,b different superscripts within a same experiment indicate statistical significance (p
    View More